Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of report (Date of earliest event reported): December 1, 2005

                         CURATIVE HEALTH SERVICES, INC.
             (Exact name of registrant as specified in its charter)

           Minnesota                  000-50371               51-0467366
(State or other jurisdiction of      (Commission           (I.R.S. Employer
 incorporation or organization)      File Number)          Identification No.)

                               61 Spit Brook Road
                           Nashua, New Hampshire 03060
               (Address of principal executive offices) (zip code)

                                 (603) 888-1500
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former name or former address, if changed since last report)


     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the 
    Exchange Act (17 CFR 240

Item 1.01         Entry into a Material Definitive Agreement.

         On December 1, 2005, Curative Health Services, Inc. and certain of its 
subsidiaries (the "Company") entered into an Asset Purchase Agreement 
(the "Agreement") to sell certain assets, properties and rights to ProCare 
Pharmacy, Inc. and ProCare Pharmacy Direct, Inc. (collectively, "ProCare") 
for a total cash consideration of $1.75 million.

         Under the Agreement, the Company will sell and ProCare will purchase or
assume certain personal property, licenses, permits, contracts, leases and
patient files related to the Company's specialty injectable and oral medications
business, including Synagis(R) (collectively, the "Purchased Assets"). In
addition, ProCare will assume and the Company will no longer be responsible for
all liabilities and obligations related to the operation of the specialty 
injectable and oral medications business and the Purchased Assets arising after
the consummation of the sale. The Agreement contains customary representations 
and covenants of the parties, and includes an agreement by the Company not to 
engage in the business of providing Synagis(R) in any territory covered by the 
Purchased Assets for three years after the closing. The Agreement will be
filed as an exhibit to the Company's Form 10-K for the fiscal year ended
December 31, 2005.

         As previously disclosed on a Form 8-K filed by the Company on June 29,
2005, Critical Care Systems, Inc., a wholly-owned subsidiary of the Company, and
PharmaCare Management Services, Inc., ProCare's affiliated pharmacy benefit
management company, entered in an Agreement for Pharmacy Services whereby the
Company became the preferred provider for specialty home infusion services for
PharmaCare's customer base, including providing nutrition support,
anti-infective therapies, pain management, immunoglobulin therapy, chemotherapy,
hydration therapy and factor products for bleeding disorders. It is anticipated
that this Agreement for Pharmacy Services will not be affected by the execution
and consummation of the Agreement.

Item 2.05         Costs Associated with Exit or Disposal Activities.

         Upon execution of the Agreement (as defined above in Item 1.01) on
December 1, 2005, the Company became committed to a plan under which certain of
its branches will close as a result of its sale of the Purchased Assets (as
defined above in Item 1.01) to ProCare. Specifically, effective December 2,
2005, the Company's specialty injectable and oral medications business,
including Synagis(R), at the following five branches will be transferred to

         Albany, New York
         Lake Charles, Louisiana
         Birmingham, Alabama
         Columbus, Mississippi
         Hurricane, West Virginia


         The Company anticipates that all of its operations at these branches
related to the specialty injectable and oral medications business will cease as
of the closing date, December 2, 2005, and all of these branches will be closed
within several weeks, except for Columbus, Mississippi, which will be operated
by ProCare.

         The Company estimates its costs to terminate property leases at
approximately $577,000, costs associated with severances, outsourcing services
and vacation payouts at approximately $379,000, miscellaneous costs at
approximately $46,000 and equipment write offs of approximately $150,000, for
total estimated costs of approximately $1,152,000. Cash expenditures related to
these costs are expected to be approximately $1,002,000. The Company expects to
record charges related to the closing of these branches in the fourth quarter of



           Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    CURATIVE HEALTH SERVICES, INC.

Date:  December 5, 2005             By:  /s/ Thomas Axmacher                
                                             Thomas Axmacher
                                             Chief Financial Officer